Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Haimin Weng"'
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 18 (2024)
Background: As a second-line therapy, oxaliplatin/fluorouracil/leucovorin (FOLFOX) remains the standard of care for patients with biliary tract cancer (BTC); however, its efficacy is suboptimal. The aim of this study was to evaluate whether, compared
Externí odkaz:
https://doaj.org/article/ed90b62e4c144338a6347050425805ca
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectiveThis study aimed to evaluate the relative efficacy and safety of first-line treatment options for metastatic castration-resistant prostate cancer (mCRPC).MethodsWe systematically searched electronic databases, including PubMed and Web of Sci
Externí odkaz:
https://doaj.org/article/e287a8e73f8d4043b424dcc6e8307b3e
Publikováno v:
Journal of Clinical Oncology. 41:520-520
520 Background: FOLFOX as second-line therapy remains the standard of care in patients with biliary tract cancer (BTC), but its efficacy is suboptimal. Currently, cytotoxic chemotherapy, targeted therapy, and immunotherapy alone or in combination are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7002f89bfe62820f945fb11847f96b35
https://doi.org/10.1200/jco.2023.41.4_suppl.520
https://doi.org/10.1200/jco.2023.41.4_suppl.520
Autor:
Qi Xu, Jingjing Li, Haimeng Tang, Hua Bao, Junrong Yan, Xue Wu, Yang Shao, Jianying Jin, Cong Luo, Haimin Weng, Jieer Ying
Publikováno v:
Cancer Research. 82:5336-5336
Introduction: The effect of trastuzumab in targeted therapy for HER2-positive gastric cancer (GC) is limited by the eventual development of resistance within patients. Although numerous studies have been published on this topic, both the mechanism of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::451a00458167d0efd465b681201e4f66
https://doi.org/10.1158/1538-7445.am2022-5336
https://doi.org/10.1158/1538-7445.am2022-5336
Autor:
Weng, Haimin1 (AUTHOR), Zeng, Pengfei2 (AUTHOR), Chen, Yuemiao3 (AUTHOR), Xu, Qi4 (AUTHOR), Ying, Jieer4,5 (AUTHOR) jieerying@aliyun.com
Publikováno v:
Clinical Medicine Insights: Oncology. 9/27/2024, p1-10. 10p.
Publikováno v:
Immunotherapy Weekly; 10/15/2024, p988-988, 1p